Cargando...
Clarithromycin synergizes with cisplatin to inhibit ovarian cancer growth in vitro and in vivo
BACKGROUND: Cisplatin-based chemotherapy is the first-line treatment for ovarian cancer. However, acquired resistance to cisplatin treatment often occurs in epithelial ovarian cancer, and effective and practical methods for overcoming this obstacle are urgently needed. The study aimed to demonstrate...
Gardado en:
| Publicado en: | J Ovarian Res |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BioMed Central
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6839134/ https://ncbi.nlm.nih.gov/pubmed/31703731 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13048-019-0570-9 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|